[144] Ionis Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Ionis Pharmaceuticals, Inc. (IONS) reports a proposed sale of 33,600 shares of common stock through Goldman Sachs & Co. LLC with an aggregate market value of $1,931,664. The filing lists approximately 159,391,229 shares outstanding and indicates an approximate sale date of 09/02/2025 on NASD. The securities being sold were primarily acquired as compensation (restricted stock units) and via option exercises on various dates between 2015 and 2020, with individual lots and quantities detailed in the filing. No securities sold in the past three months are reported.

Insights

Financial Analyst

TL;DR: Officer/insider sale notice of 33,600 shares valued at $1.93M; routine disclosure with limited market impact.

The Form 144 indicates a scheduled sale executed through Goldman Sachs for 33,600 shares valued at $1,931,664, representing a small fraction of the issuer's reported 159.4 million shares outstanding. The lots were acquired mostly as restricted stock units and option exercises between 2015 and 2020. The filing does not report any securities sold in the prior three months and contains no additional corporate or financial developments. As a disclosure, this is routine and provides transparency about insider liquidity but does not by itself signal operational changes.

Corporate Governance Expert

TL;DR: Proper Rule 144 disclosure filed; documents origin of shares and affirms no undisclosed material information.

The notice complies with Rule 144 format by identifying the broker, proposed sale date, share counts, and detailed acquisition history (RSUs and option exercises). The signer represents no knowledge of undisclosed material adverse information and the filing notes adherence to Rule 10b5-1 considerations if applicable. There are no governance or regulatory issues disclosed within the form itself; it functions as a standard insider sale notification.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	33600	1931664	159391229	09/02/2025	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	07/02/2019	Acquired as compensation -- Restricted Stock Units	The Issuer			889	07/02/2019	Compensation
Common Stock	07/03/2019	Acquired as compensation -- Restricted Stock Units	The Issuer			667	07/03/2019	Compensation
Common Stock	07/01/2019	Acquired as compensation -- Restricted Stock Units	The Issuer			667	07/01/2019	Compensation
Common Stock	07/01/2019	Acquired as compensation -- Restricted Stock Units	The Issuer			666	07/01/2019	Compensation
Common Stock	02/12/2015	Acquired upon option exercise	The Issuer			6323	02/12/2015	Option exercise
Common Stock	07/02/2020	Acquired as compensation -- Restricted Stock Units	The Issuer			889	07/02/2020	Compensation
Common Stock	07/06/2020	Acquired as compensation -- Restricted Stock Units	The Issuer			667	07/06/2020	Compensation
Common Stock	07/01/2020	Acquired as compensation -- Restricted Stock Units	The Issuer			666	07/01/2020	Compensation
Common Stock	07/01/2020	Acquired as compensation -- Restricted Stock Units	The Issuer			1778	07/01/2020	Compensation
Common Stock	07/01/2015	Acquired as compensation -- Restricted Stock Units	The Issuer			667	07/01/2015	Compensation
Common Stock	07/01/2015	Acquired as compensation -- Restricted Stock Units	The Issuer			469	07/01/2015	Compensation
Common Stock	07/02/2015	Acquired as compensation -- Restricted Stock Units	The Issuer			312	07/02/2015	Compensation
Common Stock	09/16/2020	Acquired upon option exercise	The Issuer			18940	09/16/2020	Option exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Ionis Pharmaceuticals' Form 144 filed for IONS disclose?

The filing discloses a proposed sale of 33,600 common shares through Goldman Sachs & Co. LLC with aggregate market value $1,931,664 and an approximate sale date of 09/02/2025.

How many Ionis shares outstanding are reported in the Form 144?

The Form 144 lists 159,391,229 shares outstanding.

What types of acquisitions produced the shares being sold in the IONS Form 144?

The reported shares were primarily acquired as compensation (restricted stock units) and via option exercises on dates between 2015 and 2020.

Who is the broker handling the proposed sale in the Ionis Form 144?

The broker named in the filing is Goldman Sachs & Co. LLC, located at 200 West Street, New York, NY 10282.

Does the Form 144 report any securities sold in the past three months for IONS?

No. The filing states "Nothing to Report" for securities sold during the past three months.